For FY2026 Q3, net sales were 101.016 billion yen (4.7% YoY increase), operating income was 11.035 billion yen (2.4% YoY decrease), and net income attributable to owners of the parent for the quarter was 9.374 billion yen (1.9% YoY decrease).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4095","jir_company_name":"Nippon Parkerizing Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4095-20260210-01.pdf","jir_short_summary":"For FY2026 Q3, net sales were 101.016 billion yen (4.7% YoY increase), operating income was 11.035 billion yen (2.4% YoY decrease), and net income attributable to owners of the parent for the quarter was 9.374 billion yen (1.9% YoY decrease).","jir_summary":"### Overview of Business Results\nConsolidated net sales for FY2026 Q3 reached 101.016 billion yen, a 4.7% increase YoY, marking the highest level since quarterly disclosure began. Operating income declined 2.4% YoY to 11.035 billion yen due to higher personnel and other expenses. Ordinary income slightly decreased by 0.1% YoY to 14.184 billion yen, driven by gains on foreign exchange and others. Net income attributable to owners of the parent for the quarter was 9.374 billion yen, down 1.9% YoY, reflecting gains on sales of investment securities and other factors. By segment, the Pharmaceuticals segment recorded net sales of 43.988 billion yen (1.7% YoY increase) and operating income of 7.153 billion yen (10.2% YoY decrease); the Equipment segment posted net sales of 18.556 billion yen (18.8% YoY increase) and operating income of 1.247 billion yen (214.1% YoY increase); and the Processing segment reported net sales of 36.165 billion yen (1.8% YoY increase) and operating income of 3.680 billion yen (0.6% YoY decrease).\n\n### Financial Position and Outlook\nTotal assets stood at 259.113 billion yen, down 8.136 billion yen from the previous fiscal year-end, while net assets decreased by 8.912 billion yen to 214.386 billion yen, mainly due to an increase in treasury stock. The equity ratio rose 1.9 points to 74.9%. There is no revision to the consolidated earnings guidance for FY2026, with projected net sales of 131.0 billion yen (1.0% YoY decrease), operating income of 14.0 billion yen (6.7% YoY decrease), and net income attributable to owners of the parent of 12.0 billion yen (8.5% YoY decrease). The dividend forecast remains unchanged at 50.00 yen per share.","jir_financial_highlights":"Net Sales: 101.016 billion yen (4.7% YoY increase)\nOperating Income: 11.035 billion yen (2.4% YoY decrease)\nOrdinary Income: 14.184 billion yen (0.1% YoY decrease)\nNet Income Attributable to Owners of Parent: 9.374 billion yen (1.9% YoY decrease)\nEquity Ratio: 74.9% (1.9 points increase from previous fiscal year-end)\nNet Assets per Share: 1,788.36 yen (88.20 yen increase)\nAnnual Dividend (Forecast): 50.00 yen (Same as previous year)\nCapital Expenditures: 864.2 million yen (16.0% YoY decrease)\nResearch and Development Expenses: 161.0 million yen (28.5% YoY increase)","jir_category":"","jir_hashtags":"#NipponParkerizingCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 101.016 billion yen (4.7% YoY increase)\nOperating Income: 11.035 billion yen (2.4% YoY decrease)\nNet Income Attributable to Owners of Parent: 9.374 billion yen (1.9% YoY decrease)","jir_meta_title":"Nippon Parkerizing Co., Ltd. FY2026 Q3 Financial Results: 4.7% Increase in Net Sales, 2.4% Decrease in Operating Income","jir_meta_description":"Nippon Parkerizing Co., Ltd.'s FY2026 Q3 financial summary. Net sales reached 101.016 billion yen (4.7% YoY increase), operating income was 11.035 billion yen (2.4% YoY decrease), and net income was 9.374 billion yen (1.9% YoY decrease).","jir_og_title":"Nippon Parkerizing Co., Ltd. FY2026 Q3 Financial Results Announcement","jir_og_description":"Net sales increased 4.7% YoY to 101.016 billion yen, while operating income declined 2.4% to 11.035 billion yen. Detailed results and outlook disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2024\\\",\\\"Q2 FY2024\\\",\\\"Q3 FY2024\\\",\\\"Q4 FY2024\\\",\\\"Q1 FY2025\\\",\\\"Q2 FY2025\\\",\\\"Q3 FY2025\\\",\\\"Q4 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q2 FY2026\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[283,889,325,280,303,884,337,230,318,760,328,570,362,810],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2024\\\",\\\"Q2 FY2024\\\",\\\"Q3 FY2024\\\",\\\"Q4 FY2024\\\",\\\"Q1 FY2025\\\",\\\"Q2 FY2025\\\",\\\"Q3 FY2025\\\",\\\"Q4 FY2025\\\",\\\"Q1 FY2026\\\",\\\"Q2 FY2026\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[31,790,34,270,37,270,39,490,36,540,34,820,41,690,36,910,34,130,34,160,42,050],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales by Business Segment (Cumulative Q3, million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Equipment\\\",\\\"Processing\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2026 Q3\\\",\\\"data\\\":[43988,18556,36165,2305],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\",\\\"#dc3545\\\"]},{\\\"label\\\":\\\"FY2025 Q3\\\",\\\"data\\\":[43246,15624,35536,2049],\\\"backgroundColor\\\":\\\"#6c757d\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Margin Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3\\\",\\\"FY2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Pharmaceuticals\\\",\\\"data\\\":[18.4,16.3],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Equipment\\\",\\\"data\\\":[2.5,6.7],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Processing\\\",\\\"data\\\":[10.4,10.2],\\\"borderColor\\\":\\\"#ffc107\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true,\\\"max\\\":25}}}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2026 Full-Year Earnings Guidance vs. Previous Year (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Net Sales\\\",\\\"Operating Income\\\",\\\"Ordinary Income\\\",\\\"Net Income Attributable to Owners of Parent\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[131000,14000,18500,12000],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"YoY Change Rate (%)\\\",\\\"data\\\":[-1.0,-6.7,-7.2,-8.5],\\\"type\\\":\\\"line\\\",\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false,\\\"yAxisID\\\":\\\"y1\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true},\\\"y1\\\":{\\\"position\\\":\\\"right\\\",\\\"min\\\":-10,\\\"max\\\":10,\\\"ticks\\\":{\\\"callback\\\":function(value){return value + '%';}}}}}}\"}]","ir_related_company":9030,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-27314","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n